Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deat

Trial Details

NCT ID
NCT07725406
Phase
PHASE1
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Lymphodepleting chemotherapy: Cyclophosphamide
  • Lymphodepleting chemotherapy: Bendamustine
  • Lymphodepleting chemotherapy: Fludarabine
  • Lisocabtagene Maraleucel
  • Axicabtagene Ciloleucel
  • Ciltacabtagene Autoleucel
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • For Diffuse Large B-Cell Lymphoma (DLBCL) Cohort:
  • Diagnosis of DLBCL that is refractory to first-line chemoimmunotherapy, relapses within 12 months of first-line chemoimmunotherapy, relapses after …
  • Age ≥18 years
  • ECOG performance status ≤2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →